Chen F, Liao Z, Peng D, Han L. Role of Platelet Microparticles in Blood Diseases: Future Clinical Perspectives. Ann Clin Lab Sci 2019; 49(2): 161-70.
Boilard E, Duchez AC, Brisson AJCoih. The diversity of platelet microparticles. Curr Opin Hematol 2015; 22(5): 437-44.
Varon D, Shai E. Role of platelet-derived microparticles in angiogenesis and tumor progression. Discov Med 2009; 8(43): 237-41.
Dumaswala U, Greenwalt TJT. Human erythrocytes shed exocytic vesicles in vivo. Transfusion 1984; 24(6): 490-2.
Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, et al. Drug delivery systems: An updated review. Int J Pharm Investig 2012; 2(1): 2-11.
Cho K, Wang X, Nie S, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14(5): 1310-6.
Mohan P, Rapoport N. Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. Mol Pharm 2010; 7(6): 1959-73.
Cagel M, Grotz E, Bernabeu E, Moretton MA, Chiappetta DA. Doxorubicin: nanotechnological overviews from bench to bedside. Drug Discov Today 2017; 22(2): 270-81.
Pooga M, Langel L. Synthesis of cell-penetrating peptides for cargo delivery. In: Howl J. Peptide Synthesis and Applications. Methods in Molecular Biolog, vol 298. USA: Humana Press; 2005. p. 77-89.
Jin E, Zhang B, Sun X, Zhou Z, Ma X, Sun Q, et al. Acid-active cell-penetrating peptides for in vivo tumor-targeted drug delivery. J Am Chem Soc 2013; 135(2): 933-40.
Xu P, Zuo H, Chen B, Wang R, Ahmed A, Hu Y, et al. Doxorubicin-loaded platelets as a smart drug delivery system: An improved therapy for lymphoma. Sci Rep 2017; 7: 42632.
Kailashiya J, Gupta V, Dash DJO. Engineered human platelet-derived microparticles as natural vectors for targeted drug delivery. Oncotarget 2019; 10(56): 5835-46.
Sarkar S, Alam MA, Shaw J, Dasgupta AK. Drug delivery using platelet cancer cell interaction. Pharm Res 2013; 30(11): 2785-94.
Xu P, Zuo H, Zhou R, Wang F, Liu X, Ouyang J, et al. Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: a novel targeted delivery system for lymphoma treatment with cardiopulmonary avoidance. Oncotarget 2017; 8(35): 58322-37.
Xu Y, Li W, Liang G, Peng J, Xu XJJoCB. Platelet microparticles-derived miR-25-3p promotes the hepatocyte proliferation and cell autophagy via reducing B-cell translocation gene 2. J Cell Biochem 2020 Jul 21.
Li Z, Hu S, Huang K, Su T, Cores J, Cheng K. Targeted anti–IL-1β platelet microparticles for cardiac detoxing and repair. Sci Adv 2020; 6(6): eaay0589.
Tang J, Su T, Huang K, Dinh PU, Wang Z, Vandergriff A, et al. Targeted repair of heart injury by stem cells fused with platelet nanovesicles. Nat Biomed Eng 2018; 2(1): 17-26.
Mehryab F, Rabbani S, Shahhosseini S, Shekari F, Fatahi Y, Baharvand H, et al. Exosomes as a next-generation drug delivery system: An update on drug loading approaches, characterization, and clinical application challenges. Acta Biomater 2020; 113: 42-62.
Wu YW, Huang CC, Changou CA, Lu LS, Goubran H, Burnouf T. Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop. J Biomed Sci 2020; 27(1): 1-16.
Soleymani S, Yari F, Bolhassani A, Bakhshandeh H. Platelet microparticles: An effective delivery system for anti-viral drugs. Journal of Drug Delivery Science and Technology 2019; 51: 290-6.
Sci J Iran Blood Transfus Organ 2021;18 (1): 60-69
Original Article
Comparison of different techniques for loading doxorubicin in platelets microparticles Darbandi A.1, Yari F.1, Sharifi Z.1, Rezaie N.2 1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran 2Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran Abstract Background and Objectives
Platelet microparticles are microvesicles derived from platelets. Today, with the use of nanoparticles in cancer treatments, many limitations of traditional drug delivery methods are reduced. Doxorubicin, a chemotherapeutic drug available for the treatment of many cancers, has fluorescent properties and can be detected by fluorescent imaging in tissues. Aim of this study is to compare different drug loading methods into platelet microparticles.
Materials and Methods
In this experimental study, the platelet concentrates were taken on their fifth day from Iranian Blood Transfusion Organization. Then platelet microparticles were extracted from those concentrated platelets in several centrifugation stages. Fluorescent microbeads with one-micrometer size and anti-CD41/61 antibody were used to determine the size and identity of microparticles, respectively. Doxorubicin was loaded at 10 µg/ml on platelet microparticles using three methods of incubation, cell-penetrating peptide, and Sonication. Using the auto-fluorescence property of Doxorubicin, the rate of drug loading on platelet microparticles was measured by flow cytometry method.
Results
In terms of size, 95% of the total population of microparticles was less than one micrometer. The expression levels of CD41 and CD61 were 92.39% and 80.03%, respectively. The average fluorescence light intensities calculated in each of the incubation, sonication, and CPP methods were determined to be 79.09% ± 11.37, 47.48% ± 25.12, and 56.69% ± 23.24, respectively. Conclusions
As the incubation method has higher loading percentage, it could be an effective method for loading drug in platelet microparticles. Furthermore, the use of this method can be considered for clinical studies.
Correspondence: Yari F., PhD of Immunology. Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 82052237; Fax: (+9821) 88601555
E-mail: f.yari@ibto.ir
Darbandi A, Yari F, Sharifi Z, Rezaei N. Comparison of different techniques for loading doxorubicin in platelets microparticles. Sci J Iran Blood Transfus Organ 2021; 18 (1) :60-69 URL: http://bloodjournal.ir/article-1-1363-en.html